Mesoblast Limited — Cyborg Score 7/10

Strategic Profile

The company is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms, with Ryoncil being developed for SR-aGvHD in adults and biologic-resistant inflammatory bowel disease, and rexlemestrocel-L for heart failure and chronic low back pain. Strategic partnerships include agreements with Tasly Pharmaceutical Group, JCR Pharmaceuticals Co. Ltd., and Grünenthal for development and commercialization across multiple therapeutic areas.

Cyborg Score Rationale

Recent highlights show Ryoncil net revenues increased to US$30M for the quarter. The company has a strong and extensive global intellectual property portfolio with over 1,000 granted patents or patent applications, providing commercial protection extending through to at least 2044 in all major markets. However, net income for the last half-year was −85.45M AUD.

Top Insights

• Ryoncil commercialization accelerating with US$30M quarterly net revenues as of January 2026
• Strong IP portfolio spanning 1,000+ patents with protection extending to 2044
• Dual listing on NASDAQ and ASX provides access to both US and Australian capital markets
• Strategic global partnerships in Japan, Europe, and China for market expansion and risk distribution

Named Competitors

• CAR-T and other cell therapies — Competing cell therapy approaches for hematologic malignancies
• Biologic therapies — TNF inhibitors and monoclonal antibodies for inflammatory diseases

Recent Developments

• (February 2026) Half-year financial results webcast scheduled for February 26-27, 2026
• (February 2026) High survival rates reported with Ryoncil in SR-aGvHD EIND Program
• (January 2026) Ryoncil net revenues increased to US$30M for the quarter
• (December 2025) Secured US$125 million credit facility available by June 30, 2026

Open the full interactive Mesoblast Limited report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.